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Abstract 
Creatinine clearance (CrCl) has been widely used to adjust the dosage of non-vitamin K antagonist 
oral anticoagulants in atrial fibrillation (AF) patients and exclude contraindicated patients. However, 
there are few available real-world data on the relationship between CrCl and adverse clinical 
outcomes in AF patients. Therefore, we evaluated the clinical characteristics and adverse events in 
Japanese AF patients stratified by CrCl. We categorized patients in the Fushimi AF Registry, a large 
prospective community-based Japanese cohort of AF patients, into three groups as follows: (i) CrCl 
<30 mL/min, (ii) CrCl 30-49 mL/min, and (iii) CrCl ≥50 mL/min. We evaluated 3,080 patients after 
a median follow-up of 1,076 days. Comparing with patients with CrCl ≥50 mL/min, AF patients with 
CrCl <30 mL/min showed increased risks of stroke/systemic embolism (SE) (hazard ratio (HR), 
1.68; 95% confidence interval (CI), 1.04 to 2.65; p = 0.04) and major bleeding (HR, 2.08; 95% CI, 
1.23 to 3.39; p = 0.008) after adjustment for pre-specified factors. AF patients with CrCl <30 
mL/min were also associated with higher risks of all-cause death, hospitalization for heart failure, 
myocardial infarction, or the composite of all-cause death and stroke/SE. However, no excess risk of 
stroke/SE (HR, 1.10; 95% CI, 0.76 to 1.58; p = 0.6) or major bleeding (HR, 0.98; 95% CI, 0.63 to 
1.48; p = 0.9) was noted for patients with CrCl 30-49 mL/min. In conclusion, Japanese AF patients 
with CrCl <30 mL/min were closely associated with adverse clinical events including stroke/SE and 
major bleeding.  
Key words: atrial fibrillation, creatinine clearance, stroke, major bleeding  
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Introduction 
It is well known that atrial fibrillation (AF) patients with chronic kidney disease are at higher risks 
of stroke, systemic embolism (SE), bleeding, all-cause mortality, myocardial infarction, and heart 
failure.1 A decreased estimated glomerular filtration rate was also reported to increase the risks of 
stroke, SE, and bleeding among patients with AF.2-6 All four non-vitamin K antagonist oral 
anticoagulants (NOACs) are partially eliminated via the kidney, and the estimation of creatinine 
clearance (CrCl), not glomerular filtration rate, is recommended. The Cockcroft-Gault formula for 
CrCl includes the age, sex, and body weight, but the body weight is not included in equations for the 
estimated glomerular filtration rate. Therefore, CrCl was widely used to adjust the dosage of NOACs 
and exclude contraindicated patients in four large NOAC trials7-10 and in the European Practical 
Guide.11 Although CrCl was used in some limited subanalyses of randomized control trials,3,4,12 there 
are few available real-world registry data on the relationship between CrCl and adverse clinical 
outcomes in patients with AF. To clarify that relationship, we evaluated the clinical characteristics 
and adverse clinical events including stroke/SE, major bleeding, death, hospitalization for heart 
failure, and myocardial infarction13,14 in Japanese AF patients stratified by CrCl.     
 
Methods 
The Fushimi AF Registry is a community-based prospective all-comer cohort study of AF patients 
who visited the participating medical institution in the Fushimi district, Kyoto, Japan, which is a 
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densely populated urban area with a total population of 283,000. We enrolled AF patients defined by 
the documentation of AF on a 12-lead electrocardiogram or Holter monitoring at any time with no 
exclusion criteria from March 2011. The detailed study design, patient enrollment, definition of the 
measurements, and subjects’ baseline clinical characteristics of the Fushimi AF Registry were 
previously described elsewhere (UMIN Clinical Trials Registry: UMIN000005834).15-19 Oral 
anticoagulant (OAC) included warfarin, dabigatran, rivaroxaban, and apixaban, and the assignment 
to the OAC group was based on OAC usage at the time of enrollment. This study was conducted in 
accordance with the amended Declaration of Helsinki and the study protocol was approved by the 
ethical committees of the National Hospital Organization Kyoto Medical Center and Ijinkai Takeda 
General Hospital. 
We excluded the patients on hemodialysis and without baseline CrCl data. The CrCl was 
calculated with the Cockcroft-Gault formula,20 and patients were categorized into three groups as 
follows: (i) CrCl <30 mL/min, (ii) CrCl 30-49 mL/min, and (iii) CrCl ≥50 mL/min.  
Clinical outcomes evaluated in this study were stroke/SE, major bleeding, all-cause death, 
hospitalization for heart failure, myocardial infarction, and the composite of all-cause death and 
stroke/SE. Stroke was defined as the sudden onset of a focal neurologic deficit in a location 
consistent with the territory of a major cerebral artery, and the diagnosis was confirmed by computed 
tomography or magnetic resonance imaging. SE was defined as an acute vascular occlusion of an 
extremity or organ other than the brain. Major bleeding was defined as a reduction in the hemoglobin 
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level by at least 2 g/dL, transfusion of at least 2 units of blood, or clinically overt bleeding in a 
critical area or an organ, according to the definition by the International Society on Thrombosis and 
Haemostasis.16,21 Hospitalization for heart failure was defined as an admission to the hospital and the 
final diagnosis at discharge was heart failure by each attending physician. The diagnosis of 
myocardial infarction was made by the charged physician who was recommended to follow the third 
universal definition of myocardial infarction.22  
The risk of stroke was assessed by the CHADS2 score23 or the CHA2DS2-VASc score,24 and the 
bleeding risk was estimated by the HAS-BLED score.25 In this analysis, “V” in the CHA2DS2-VASc 
score was defined by prior myocardial infarction or peripheral vascular disease. In the HAS-BLED 
score, “L” was not assessed because international normalized ratio data were unavailable in the 
present study and drugs of “D” were replaced by the concomitant use of antiplatelets based on a 
modified HAS-BLED score.26  
Categorical variables are expressed as numbers and percentages and compared using the 
chi-square test. Continuous variables of each group are presented with the mean ± standard deviation 
and compared using Student’s t-test or the Wilcoxon rank-sum test based on their distributions. The 
cumulative incidence of stroke/SE, major bleeding, all-cause death, hospitalization for heart failure, 
myocardial infarction, and the composite of all-cause death/stroke/SE were estimated by the 
Kaplan-Meier method, and differences were assessed with the log-rank test. The adjusted 
relationships between CrCl and the adverse clinical events were evaluated using Cox proportional 
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hazard models. 
To adjust the baseline characteristics for the assessment of stroke/SE, we adopted 8 components of 
the CHA2DS2-VASc stroke risk score, such as congestive heart failure, hypertension, age 75 years or 
older, diabetes mellitus, prior cerebral ischemia, vascular disease, age 65-74 years old, and a female 
sex, and added one factor on the status of OAC consumption. Therefore, nine factors were finally 
adjusted. We also adopted 7 components of the HAS-BLED bleeding risk score: hypertension, 
abnormal liver function, prior stroke, history of major bleeding, age 65 years or older, drug usage, 
and alcohol abuse, and added the status of OAC treatment. Therefore, eight factors were entered into 
a multivariate Cox proportional hazard model to adjust and evaluate the risk of bleeding. For the 
multivariate model, we excluded abnormal renal function as a HAS-BLED risk factor in order to 
avoid the confounding effects to evaluate the relationship between CrCl, which was mainly 
dependent on the renal function, and adverse clinical outcomes. The results of analyses are shown as 
the hazard ratio (HR) with 95% confidence intervals (CIs) and p values. Results were considered 
significant with a p value of <0.05. We used JMP 12.0 (SAS Institute Inc., Cary, NC, USA) for all 
analyses. The authors had full access to the data and take responsibility for its integrity.   
 
Results 
Of the 4,115 patients enrolled in the Fushimi AF Registry by the end of July 2014, 3,080 patients 
who were categorized by CrCl were finally analyzed (Fig 1). The numbers of patients categorized 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT  
7 
into CrCl <30, CrCl 30-49, and CrCl ≥50 mL/min group were 322 (10%), 814 (26%), and 1,944 
(63%), respectively. The median follow-up was 1,076 days (interquartile range, 448 to 1,315).  
Baseline characteristics were significantly different among patients categorized by CrCl (Table 1). 
Amongst the 3,080 patients analyzed, 1,671 patients (54%) were treated with OAC. Baseline 
characteristics of patients with or without OAC are given in Table 2, and those of patients with or 
without OAC in each CrCl category are given in Table 3.  
The incidences of stroke/SE in patients stratified by CrCl were significantly different (p = 0.0002) 
(Fig 2A). Kaplan-Meier curves for the incidences of stroke/SE in patients with and without OAC are 
shown in Figure 2B and 2C, respectively. 
After adjustment for pre-specified factors, patients with CrCl <30 mL/min had a significantly 
higher risk of stroke/SE compared with patients with CrCl ≥50 mL/min (HR, 1.68; 95% CI, 1.04 to 
2.65; p = 0.04), but no significant difference was seen in patients with CrCl 30-49 mL/min (HR, 
1.10; 95% CI, 0.76 to 1.58; p = 0.6) (Table 4). Besides CrCl categories, elderly (≥75 years old) (HR, 
1.97; 95% CI, 1.19 to 3.44; p = 0.008) and prior stroke/TIA/SE (HR, 1.79; 95% CI, 1.30 to 2.45; p = 
0.0005) were significantly correlated with stroke/SE. After adjustment for factors including the renal 
function, OAC use was not associated with stroke (HR, 1.06; 95% CI, 0.78 to 1.44; p = 0.7). 
Kaplan-Meier curves for the incidences of major bleeding among patients stratified by CrCl are 
shown in Figure 3A, and those of patients treated with or without OAC are shown in Figure 3B and 
3C, respectively. The highest rates of major bleeding in the CrCl <30 mL/min group were observed 
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in the entire cohort and cohort without OAC, but not in those taking OAC.  
After adjustment for factors composed of the HAS–BLED score and status of OAC prescription, 
patients with CrCl <30 mL/min had a significantly higher risk of major bleeding (HR, 2.08; 95% CI, 
1.23 to 3.39; p = 0.008), compared with patients with CrCl ≥50 mL/min (Table 5). However, patients 
with CrCl 30-49 mL/min showed no significant difference (HR, 0.98; 95% CI, 0.63 to 1.48; p = 0.9). 
Only a history of major bleeding (HR, 3.69; 95% CI, 1.95 to 6.48; p = 0.0002) and an elderly age 
(>65 years old) (HR, 1.82; 95% CI, 1.07 to 3.29, p = 0.03) were significantly correlated with major 
bleeding. After adjustment for pre-specified factors including CrCl, OAC use was not significantly 
correlated with major bleeding (HR, 1.41; 95% CI, 0.99 to 2.03, p = 0.06). 
Kaplan-Meier curves for other adverse clinical events, such as all-cause death, hospitalization for 
heart failure, myocardial infarction, and the composite of all-cause death and stroke/SE are shown in 
Supplementary Data. The incidences of all these adverse events were the highest in patients with 
CrCl <30 mL/min.  
 
Discussion 
In the present study, we evaluated the relationship between CrCl and adverse clinical outcomes in 
patients with AF. Patients with CrCl <30 mL/min were excluded in three large NOAC trials,7,8,10 and 
three NOACs were recommended for dosage reduction in patients with CrCl <50 mL/min and the 
other NOAC was recommended for reduction in patients with CrCl <30 mL/min in the European 
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Practical Guide.11 Therefore, we categorized patients into three groups as follows: (i) CrCl <30 
mL/min, (ii) CrCl 30-49 mL/min, and (iii) CrCl ≥50 mL/min. Our results revealed novel findings 
that patients with CrCl <30 mL/min had the greatest risks of stroke/SE, major bleeding, all-cause 
death, hospitalization for heart failure, myocardial infarction, and the composite of all-cause death 
and stroke/SE. Although the sub-analyses of ARSITOTLE3 and ROCKET-AF12 trials both showed 
that CrCl <60 mL/min was a strong predictor of stroke/SE or major bleeding, no additional risk was 
observed in AF patients with CrCl 30-49 mL/min compared with patients in the CrCl ≥50 mL/min 
category in our cohort. The reasons for this discrepancy might be as follows: (1) There was a racial 
difference; (2) The median body weight was about 80 kg in previous reports, whereas it was about 60 
kg in our report. This is the first real-world registry data on the relationship between CrCl and 
adverse clinical outcomes in patients with AF. The results of this study may help physicians to adjust 
the dosage of the treatment for AF patients with NOACs in daily clinical practice and exclude 
contraindicated patients. 
In our analysis, the crude incidence of stroke/SE in patients with CrCl <30 mL/min treated with 
OAC was paradoxically higher than in patients not treated with OAC. This might be partially 
explained by the patients prescribed OAC exhibiting higher incidences of comorbidities, although 
the CHA2DS2-VASc score was comparable between with and without OAC treatment in patients 
with CrCl <30 mL/min. In a multicenter registry enrolling patients undergoing first percutaneous 
coronary intervention in Japan, Goto et al. reported similar results showing that the cumulative 
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5-year incidence of stroke in patients treated with OAC was not different from that in patients 
without OAC (13.8 vs. 11.8%, respectively, p = 0.49) in 1,057 AF patients.27 The crude incidence of 
major bleeding in patients with CrCl <30 mL/min treated with OAC in the current study was also 
paradoxically lower than in patients not treated with OAC. The initiation of OAC treatment was left 
to the discretion of the charged physician, which undoubtedly resulted in selection bias, although the 
HAS-BLED score and history of major bleeding were comparable between with and without OAC 
treatment in patients with CrCl <30 mL/min. However, the factor closely related to stroke and major 
bleeding is the quality of anticoagulation control,28 as reflected by the average time in the therapeutic 
range, which was not available in our cohort. 
Apart from CrCl <30 mL/min, an elderly age (≥75 years old) and prior stroke/TIA/SE were 
significantly correlated with stroke/SE. Patients with a history of major bleeding and an elderly age 
(>65 years old) also had an increased risk of major bleeding after adjustment for the HAS-BLED risk 
factors and status of OAC prescription. Importantly, after adjusting for factors including CrCl, OAC 
use was not independently associated with an excess of stroke or major bleeding. This study was not 
a randomized trial and there were a number of confounders for choosing each drug. Therefore, we 
did not examine the event rates based on each type of OAC.  
Some limitations merit emphasis. First, this was a prospective observational study; therefore, it 
only shows associations, and not causality. Second, about 10% of patients were lost during follow-up, 
which could undoubtedly result in a selection bias. Third, this study involved AF patients recruited 
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from a small region of Japan, and so the study results may not be applicable to other Asian (or 
non-Asian) populations. Fourth, the statistical analysis was based only on OAC usage at the time of 
enrollment. This did not take into account the initiation, adherence, and switching of OACs, or the 
quality of the adjustment such as the time in therapeutic range for patients taking warfarin through 
the follow-up period.  
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FIGURE LEGENDS 
Figure 1 
Patient flowchart for the present analysis.  
AF = atrial fibrillation; CrCl = creatinine clearance.  
Figure 2  
Unadjusted Kaplan-Meier curves for the incidences of stroke/SE in the entire cohort (A) and in 
patients treated with (B) or without (C) OAC.  
CrCl = creatinine clearance; OAC = oral anticoagulant; SE = systemic embolism.  
Figure 3  
Unadjusted Kaplan-Meier curves for the incidences of major bleeding in the entire cohort (A) and in 
patients treated with (B) or without (C) OAC.  
CrCl = creatinine clearance; OAC = oral anticoagulant.  
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Table 1: Baseline Characteristics of Patients Categorized by CrCl 
 
Variable CrCl <30 
(n = 322) 
30≤ CrCl <50 
(n = 814) 
50≤ CrCl 
(n = 1,944) 
p Value 
Age (years) 
≥75 
65-74 years old 
Female 
Body weight (kg) 
Body mass index (kg/m2) 
Systolic BP (mmHg) 
Diastolic BP (mmHg) 
Heart rate (beats/min) 
Symptomatic 
 Palpitation 
Hemoglobin (g/dL) 
Platelet count (×109/L) 
Baseline renal function 
Serum creatinine (mg/dL) 
Estimated glomerular filtration rate 
(mL/min/1.73 m2) 
Calculated creatinine clearance 
(mL/min) 
Comorbidities 
Heart failure 
Hypertension 
Diabetes mellitus 
 Receiving insulin therapy 
 Prior stroke 
Prior stroke/TIA 
History of major bleeding  
Dyslipidemia 
 Coronary artery disease 
Prior myocardial infarction 
Peripheral vascular disease 
COPD 
Abnormal liver function 
84.0 ± 8.1 
283 (88%) 
33 (10%) 
203 (63%) 
47.8 ± 10.5 
20.5 ± 3.4 
121.2 ± 22.1 
65.4 ± 14.3 
78.4 ± 19.3 
139 (43%) 
72 (22%) 
10.7 ± 1.7 
188 ± 69 
 
1.8 ± 1.2 
29.6 ± 11.1 
 
21.5 ± 5.9 
 
 
187 (58%) 
214 (66%) 
72 (22%) 
17 (5.3%) 
84 (26%) 
86 (27%) 
19 (5.9%) 
126 (39%) 
78 (24%) 
47 (15%) 
9 (2.8%) 
21 (6.5%) 
9 (2.8%) 
80.5 ± 7.1 
662 (81%) 
135 (17%) 
430 (53%) 
52.7 ± 10.6 
21.8 ± 3.5 
124.0 ± 19.4 
68.3 ± 12.5 
77.9 ± 16.2 
378 (46%) 
229 (28%) 
12.2 ± 1.8 
196 ± 74 
 
1.0 ± 0.3 
50.8 ± 12.9 
 
41.0 ± 5.6 
 
 
316 (39%) 
548 (67%) 
194 (24%) 
30 (3.7%) 
169 (21%) 
183 (22%) 
32 (3.9%) 
353 (43%) 
147 (18%) 
53 (6.5%) 
53 (6.5%) 
65 (8.0%) 
10 (1.2%) 
69.8 ± 9.8 
689 (35%) 
776 (40%) 
623 (31%) 
63.8 ± 12.5 
24.0 ± 3.9 
125.1 ± 17.2 
71.8 ± 12.0 
77.9 ± 15.1 
945 (49%) 
697 (36%) 
13.6 ± 1.7 
202 ± 66 
 
0.8 ± 0.2 
71.9 ± 19.3 
 
78.0 ± 25.2 
 
 
407 (21%) 
1,190 (61%) 
485 (25%) 
60 (3.1%) 
307 (16%) 
337 (17%) 
71 (3.7%) 
909 (47%) 
251 (13%) 
96 (4.9%) 
446 (12%) 
69 (3.6%) 
31 (1.6%) 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
0.002 
<0.0001 
0.9 
0.2 
<0.0001 
<0.0001 
0.001 
 
<0.0001 
<0.0001 
 
N/A 
 
 
<0.0001 
0.005 
0.5 
0.2 
<0.0001 
<0.0001 
0.2 
0.02 
<0.0001 
<0.0001 
<0.0001 
0.001 
0.2 
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History of catheter ablation 
History of defibrillation 
CHADS2 score 
CHA2DS2-VASc score 
HAS-BLED score 
Basal medications 
OAC prescription 
 Warfarin 
  PT-INR value 
 Dabigatran 
 Rivaroxaban 
 Apixaban 
Antiplatelet prescription 
Number of antiplatelets  
8 (2.5%) 
12 (3.7%) 
2.9 ± 1.3 
4.7 ± 1.4 
2.0 ± 1.0 
 
146 (45%) 
136 (42%) 
1.9 ± 0.5 
6 (1.9%) 
2 (0.6%) 
2 (0.6%) 
119 (37%) 
0.5 ± 0.6 
28 (3.4%) 
25 (3.1%) 
2.6 ± 1.2 
4.2 ± 1.4 
1.7 ± 0.8 
 
481 (59%) 
433 (53%) 
1.9 ± 0.5 
20 (2.5%) 
19 (2.3%) 
9 (1.1%) 
270 (33%) 
0.4 ± 0.6 
133 (6.8%) 
76 (3.9%) 
1.8 ± 1.3 
2.9 ± 1.6 
1.5 ± 0.9 
 
1,044 (54%) 
863 (44%) 
1.8 ± 0.5 
97 (5.0%) 
54 (2.8%) 
30 (1.5%) 
498 (26%) 
0.3 ± 0.5 
<0.0001 
0.6 
<0.0001 
<0.0001 
<0.0001 
 
0.0001 
<0.0001 
0.08 
0.0005 
0.03 
0.3 
<0.0001 
<0.0001 
BP = blood pressure; COPD = chronic obstructive pulmonary disease; CrCl = creatinine clearance; OAC = oral 
anticoagulant; PT-INR = prothrombin time-international normalized ratio; TIA = transient ischemic attack. 
Values are mean ± SD or n (%).  
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Table 2: Baseline Characteristics of Patients With or Without Oral Anticoagulant Prescription  
 
Variable OAC prescription  p Value 
Yes  
(n = 1,671) 
No  
(n = 1,409) 
Age (years) 
≥75 
65-74 years old 
Female 
Body weight (kg) 
Body mass index (kg/m2) 
Systolic BP (mmHg) 
Diastolic BP (mmHg) 
Heart rate (beats/min) 
Symptomatic 
 Palpitation 
Hemoglobin (g/dL) 
Platelet count (×109/L) 
Baseline renal function 
Serum creatinine (mg/dL) 
Estimated glomerular filtration rate 
(mL/min/1.73 m2) 
Calculated creatinine clearance 
(mL/min) 
Comorbidities 
Heart failure 
Hypertension 
Diabetes mellitus 
 Receiving insulin therapy 
 Prior stroke 
Prior stroke/TIA 
History of major bleeding  
Dyslipidemia 
 Coronary artery disease 
Prior myocardial infarction 
Peripheral vascular disease 
74.2 ± 9.3 
893 (54%) 
542 (32%) 
648 (39%) 
60.0 ± 13.3 
23.3 ± 4.0 
123.3 ± 18.0 
70.1 ± 12.5 
77.6 ± 15.7 
778 (47%) 
491 (29%) 
13.0 ± 1.9 
197 ± 69 
 
1.0 ± 0.6 
60.1 ± 20.5 
 
60.9 ± 26.4 
 
 
607 (36%) 
1,100 (66%) 
434 (26%) 
53 (3.2%) 
369 (22%) 
405 (24%) 
61 (3.7%) 
772 (46%) 
248 (15%) 
102 (6.1%) 
79 (4.7%) 
74.0 ± 12.1 
736 (52%) 
402 (29%) 
608 (43%) 
58.2 ± 13.3 
22.8 ± 3.9 
125.7 ± 18.8 
70.3 ± 12.7 
78.4 ± 16.1 
684 (49%) 
507 (36%) 
12.8 ± 2.1 
201 ± 69 
 
0.9 ± 0.5 
64.0 ± 24.1 
 
63.9 ± 32.5 
 
 
303 (22%) 
852 (60%) 
317 (23%) 
54 (3.8%) 
191 (14%) 
201 (14%) 
61 (4.3%) 
616 (44%) 
228 (16%) 
94 (6.7%) 
52 (3.7%) 
0.7 
0.4 
0.02 
0.01 
0.0002 
  <0.0001 
 0.0005 
0.7 
0.2 
0.3 
<0.0001 
0.0007 
0.12 
 
0.01 
<0.0001 
 
0.005 
 
 
<0.0001 
0.002 
0.03 
0.3 
<0.0001 
<0.0001 
0.3 
0.2 
0.3 
0.5 
0.2 
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COPD 
Abnormal liver function 
History of catheter ablation 
History of defibrillation 
CHADS2 score 
CHA2DS2-VASc score 
HAS-BLED score 
Basal medications 
Antiplatelet prescription 
Number of antiplatelets 
105 (6.3%) 
27 (1.6%) 
91 (5.5%) 
67 (4.0%) 
2.3 ± 1.3 
3.7 ± 1.6 
1.6 ± 0.9 
 
393 (24%) 
0.3 ± 0.5 
71 (5.0%) 
23 (1.6%) 
78 (5.5%) 
46 (3.3%) 
1.9 ± 1.3 
3.2 ± 1.7 
1.6 ± 0.9 
 
494 (35%) 
0.4 ± 0.6 
0.1 
1.0 
0.9 
0.3 
<0.0001 
<0.0001 
0.3 
 
<0.0001 
<0.0001 
BP = blood pressure; COPD = chronic obstructive pulmonary disease; OAC = oral anticoagulant; TIA = transient 
ischemic attack. 
Values are mean ± SD or n (%).  
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Table 3: Baseline Characteristics of Patients Categorized by CrCl and OAC 
 
Variables 
CrCl <30 p 
Value 
CrCl 30-49 p 
Value OAC+ 
(n = 146) 
OAC-  
(n = 176) 
p Value OAC- 
(n = 333) 
Age (years) 
Prior stroke 
History of major bleeding 
CHADS2 score 
CHA2DS2-VASc score 
HAS-BLED score 
82.0 ± 7.3 
43 (29%) 
6 (4.1%) 
2.9 ± 1.3 
4.7 ± 1.5 
2.0 ± 1.0 
85.6 ± 8.3 
41 (23%) 
5 (2.8%) 
2.9 ± 1.3 
4.6 ± 1.4 
2.0 ± 0.9 
<0.0001 
0.2 
0.6 
0.8 
0.6 
0.7 
79.6 ± 6.7 
104 (22%) 
15 (3.1%) 
2.7 ± 1.2 
4.3 ± 1.4 
1.7 ± 0.8 
81.8 ± 7.3 
65 (20%) 
15 (4.5%) 
2.4 ± 1.3 
4.1 ± 1.4 
1.8 ± 0.9 
<0.0001 
0.5 
0.3 
0.004 
0.1 
0.03 
 
Variables 
CrCl ≥50 p 
Value OAC+ 
(n = 1,044) 
OAC- 
(n = 900) 
Age (years) 
Prior stroke 
History of major bleeding 
CHADS2 score 
CHA2DS2-VASc score 
HAS-BLED score 
70.6 ± 8.7 
222 (21%) 
20 (1.9%) 
2.1 ± 1.3 
3.3 ± 1.6 
1.5 ± 0.9 
68.9 ± 11.0 
85 (9.4%) 
24 (2.7%) 
1.4 ± 1.2 
2.6 ± 1.5 
1.4 ± 0.9 
<0.0001 
<0.0001 
0.3 
<0.0001 
<0.0001 
0.009 
CrCl = creatinine clearance; OAC = oral anticoagulant. 
Values are mean ± SD or n (%).  
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Table 4: Univariate and Multivariate Analysis of the Risk Factors for Stroke/SE 
 
Variables Univariate  Multivariate 
Hazard ratio 
(95% CI) 
 Hazard ratio 
(95% CI) 
p Value 
CrCl <30 (vs. CrCl ≥50) 
30≤ CrCl <50 (vs. CrCl ≥50) 
OAC prescription  
Congestive heart failure 
Hypertension 
Age, ≥75 years old 
Age, 65-74 years old 
Diabetes mellitus 
Prior stroke/TIA/SE 
Vascular disease 
Female sex 
2.05 (1.34 to 3.02) 
1.29 (0.93 to 1.76) 
1.17 (0.87 to 1.58) 
1.27 (0.92 to 1.72) 
1.12 (0.83 to 1.53) 
2.12 (1.56 to 2.92) 
0.59 (0.41 to 0.82) 
1.10 (0.79 to 1.51) 
2.00 (1.46 to 2.71) 
1.22 (0.75 to 1.88) 
1.03 (0.76 to 1.38) 
 1.68 (1.04 to 2.65) 
1.10 (0.76 to 1.58) 
1.06 (0.78 to 1.44) 
1.06 (0.76 to 1.47) 
1.06 (0.78 to 1.45) 
1.97 (1.19 to 3.44) 
1.09 (0.64 to 1.96) 
1.08 (0.77 to 1.50) 
1.79 (1.30 to 2.45) 
1.00 (0.61 to 1.55) 
0.88 (0.64 to 1.20) 
0.04 
0.6 
0.7 
0.7 
0.7 
0.008 
0.8 
0.6 
0.0005 
1.0 
0.4 
CI = confidence interval; CrCl = creatinine clearance; OAC = oral anticoagulant; SE = systemic embolism; TIA = 
transient ischemic attack. 
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Table 5: Univariate and Multivariate Analysis of the Risk Factors for Major Bleeding 
 
Variables Univariate  Multivariate 
Hazard ratio 
(95% CI) 
 Hazard ratio 
(95% CI) 
p Value 
CrCl <30 (vs. CrCl ≥50) 
30≤ CrCl <50 (vs. CrCl ≥50) 
OAC prescription  
Hypertension, SBP >160mmHg 
Abnormal liver function 
Prior stroke 
History of major bleeding 
Age, >65 years old 
Antiplatelet prescription 
Alcohol abuse 
2.14 (1.31 to 3.34) 
0.98 (0.65 to 1.44) 
1.33 (0.94 to 1.90) 
1.32 (0.41 to 3.14) 
1.36 (0.22 to 4.27) 
1.31 (0.86 to 1.95) 
3.44 (1.89 to 5.77) 
1.97 (1.19 to 3.51) 
1.40 (0.98 to 1.98) 
1.30 (0.87 to 1.90) 
 2.08 (1.23 to 3.39) 
0.98 (0.63 to 1.48) 
1.41 (0.99 to 2.03) 
1.40 (0.43 to 3.33) 
1.48 (0.24 to 4.68) 
0.87 (0.55 to 1.35) 
3.69 (1.95 to 6.48) 
1.82 (1.07 to 3.29) 
1.41 (0.98 to 2.01) 
1.48 (0.98 to 2.19) 
0.008 
0.9 
0.06 
0.5 
0.6 
0.5 
0.0002 
0.03 
0.07 
0.06 
CI = confidence interval; CrCl = creatinine clearance; OAC = oral anticoagulant; SBP = systolic blood pressure.  
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